10 TH ANNIVERSARY Summary report on CQDM economic impact - - PowerPoint PPT Presentation

10

TH

ANNIVERSARY

Summary report on CQDM economic impact 2008-2018

Presented by : Diane Gosselin, CEO Novembre 2018

3

Founded in in 2008 by Vis isionaries

Paul Lévesque Bernard Prigent Max Fehlmann Philippe Walker Alain Beaudet Dawn Graham

4

A Uniq ique Coll llaborativ ive Model in in 2008

◼

Pharma driven

◼

A collaborative ground between the private and academic sectors

◼

An emerging model in 2008

◼

A lot of skepticism towards the CQDM model

MISSION : ACCELERATE DRUG DISCOVERY AND DEVELOPMENT

5

A Sig ignific icant Fin inancia ial Leverage to Fill ill the Gap

PHARMA GOVERNMENTS CO-FUNDING PARTNERS

6

PHARMA GOVERNMENTS

A Sig ignific icant Fin inancia ial Leverage to Fill ill the Gap

CO-FUNDING PARTNERS

7

GOVERNMENTS CO-FUNDING PARTNERS

A Sig ignific icant Fin inancia ial Leverage to Fill ill the Gap

8

◼ Stimulate innovation by supporting early stage

translational research

◼ Bridge academic research to the private sector ◼ Generate benefits for the academic and private

sectors

◼ Address critical needs of the bio-pharmaceutical

research

A Sig ignific icant Fin inancia ial Leverage to Fill ill the Gap

HIGH-RISK, HIGH-REWARD PROJECTS

9

The survey reflects the point

• f view of the

INVESTIGATORS

A Survey to Measure the Im Impact of CQDM

AREAS COVERED

◼

Enabling technologies, products and services generated

◼

Impact on the creation and growth of SMEs

◼

Additional funding for academic institutions and SMEs

◼

Follow-on partnerships with the pharma industry

◼

Jobs and trainings

◼

Outreach SOURCE OF QUANTITATIVE AND QUALITATIVE INFORMATION

◼

Annual and quarterly reports from the projects

◼

In depth survey on 64 projects

◼

Over 100 people interviewed (investigators and entrepreneurs involved in the projects) Under the leadership of Gilles Duruflé, Economist

OVERALL OBJECTIVE

Scale the impact of funded projects on the ecosystem The survey reflects the point of view of the INVESTIGATORS

10

Searchin ing for Scie ientific Excellence, , In Innovation and Im Impact

$68M

FUNDING

$44M CQDM $24M Co-funding partners

1200

RESEARCHERS

165 academic labs 31 SMEs

64

PROJECTS

25 Qc only 11 Qc & International 16 Qc & others provinces 12 outside Qc

10

FUNDING PROGRAMS

49 calls for proposals 825 proposals reviewed

11

STRATEGIC LEVERAGE:

◼ ACCELERATE INNOVATION ◼ INCREASE OUTREACH ◼ STIMULATE COMPANY GROWTH ◼ ENHANCE COMPETITIVENESS

A Number of Partnership ips Fostered

31

SMEs

165

ACADEMIC LABS

10

LEADING PHARMA

12

64 projects funded

47 completed 5 terminated 12 active

88% success rate

deliverables achieved during funding

500 products, services

and research tools

generated from CQDM projects

13

Dia iagnostics and Research Tools Develo loped

309

RESARCH TOOLS

11

Discovery

17

Clinical validation

2

Market

30

DIAGNOSTICS

14

INSTRUMENTS

5

Discovery

3

Prototype

6

Market

100

Assays

68

Animal models

55

Cell lines

20

Methods & Processes

13

Softwares

9

Databases

265

OTHER TOOLS

14

Several Therapeutic ics Generated from Pla latforms

56

PLATFORMS Drug discovery Drug delivery Drug screening

Developed Used in research/ Commercialized Validated

105

Discovery

21

Preclinical

2

Phase I

2

Phase II

1

Phase III

131 THERAPEUTICS IN DEVELOPMENT

15

The Medic icago Example

VLPExpress discovery platform CQDM funding Publicly owned Market cap: $80M 65 employees Pandemic Influenza vaccine - Phase I Pandemic influenza Phase II New programs initiated Rotavirus Seasonal influenza 3 undisclosed Privately owned Raised over $300M in investment 350 employees $245M Factory Investment (Quebec)

2009 2010 2011 2012 2013 2014 2015 2016 2017 2018

Norovirus Manufacturing optimization Ebola Seasonal Influenza : Phase III Rotavirus: Phase I Norovirus: preclinical

16

More than $194M in in Follow-on In Investments

for r the the de development of

• f CQDM-funded technologie

ies

CONSORTIA PUBLIC AGENCIES PRIVATE FOUNDATIONS INVESTORS PRIVATE COMPANIES

SOURCE OF FUNDS SMEs Pharma $10M $20M $30M $40M $50M

17

CQDM-FUNDED PROJECTS

520 FTEs x year supported

(including 191 students trained) A network of 1200 researchers (136 mentors from global pharma)

Jo Jobs and Trainings Supported

1200

FTEs x year highly skilled resources

(estimated)

FOLLOW-ON

18

◼ 6 Start-ups ◼ Growth of 40 existing companies ◼ 1 foreign company established in

Quebec

A Colla llaborative Approach that Generates Benefit its for SMEs

31

SMEs

165

ACADEMIC LABS

10

LEADING PHARMA

19

0% 20% 40% 60% 80% 100%

FUND RAISING PARTNERSHIPS WITH PHARMA UNIQUE FUNDING FOR R&D INCREASED RESEARCH CAPACITY DEVELOPMENT OF NEW PRODUCTS ACCES TO INNOVATION

Benefits Generated for SMEs

% positive responses among entrepreneurs interviewed

20

SUPPORT OF CQDM FUNDED PROJECTS

◼ $14M initial funding ◼ 136 mentors from global Pharma ◼ Market pull approach

PARTNERS FOR THE FUTURE

◼ 71 follow-on interactions and

partnerships with 26 different Pharma

◼ $41M follow-on investments

Benefits Generated from the Phama

31

SMEs

165

ACADEMIC LABS

10

LEADING PHARMA

21

50 100 150 200 250 300

$M invested

A Very ry Im Impressiv ive Fin inancial Leverage

4.2 .2x

$1 of Qc government funding generates

$13.2 total funding

Funding of CQDM projects (64) QC GOV.

$1 of Qc government funding generates

$4.2 for R&D

Follow-on investments

13.2x

22

Conclusion

• A CATALYST TO THE CULTURE OF COLLABORATIVE INNOVATION
• TRANSFORMATIVE EFFECT GENERATED FROM FUNDING
• A MODEL THAT DELIVERS HIGH VALUE PRODUCTS AND SERVICES
• FILLS THE GAP TO FOSTER INNOVATION

IMPACT BEYOND EXPECTATIONS

23

Breaking up the Silo ilos to Conquer the Future

24

A D Dedic icated Team

Diane Gosselin Michael Bridges Mario Chevrette Naëla Janmamode Mathieu Perrée Marc Thibault Steven Xanthoudakis Jennifer Saleeb Véronique Dugas Rebeca Baca-Diaz Olivier Carter

25

An Exp xperie ienced Board

Chairman Richard Fajzel, CEO, Exactis Innovation Members Jennifer Chan, VP, Policy and Communications, Merck Canada Diane Gosselin, President and CEO, CQDM Raphael Hofstein, President and CEO, MaRS Innovation Ken Pastor, General Partner, CTI Capital Louise Proulx, Chief Development Officer, Therillia Jorge Puente, Managing Partner, Pleasanton Pharma Ventures Rémi Quirion, Quebec Chief Scientist Uwe Schoenbeck, Senior VP & CSO, External R&D Innovation, Pfizer worldwide R&D Ali Tehrani, Co-founder, President and CEO, Zymeworks Patrick J. Wier, Senior VP, In Vitro/In Vivo Translation Platform, GSK Chairman Daniel Hétu, Managing Director, Lumira Capital Members Karen Akinsanya, Chief Biomedical Scientist, Schrödinger André Darveau, Vice Rector, Administration, Université Laval Diane Gosselin, President and CEO, CQDM Reid Jason Leonard, Senior VP, Corporate Development, Potenza Therapeutics Mark Lim, Assistant Director of Global Public Health Programs, American Society for Microbiology

A Rig igorous Scie ientific Advis isory Board

26

An Ext xtended Canadian and In International Partner Network